AXA (ENXTPA:CS) Stock Trades Below Peers Despite 18% ROE

Investors pushed AXA to €44.94 at the 31 July close, capping a steady run over the past quarter. The stock looks calm on the screen while the earnings print tells a stronger story. Underlying earnings per share rose 8% in the first half and return on equity landed at 18%. That is a punchy outcome for a global insurer that still trades on a trailing P/E of 12.7x, below peers.

The market focused on the day’s move. Long term investors will likely focus on that earnings power and the confirmation of solid capital through a 218% Solvency II ratio.

Is AXA at €44.94 a genuine bargain given high quality earnings and an 18% ROE, or is the discount to peers sending a different signal? See how the current price compares with our valuation analysis for AXA

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): €47,995m vs. €46,696m (up about 2.8%)
• Net Income (Excl. Extra Items, H1 2026 vs. H1 2025): €3,558m vs. €3,716m (down about 4.3%)
• Basic EPS (H1 2026 vs. H1 2025): €1.71 vs. €1.72 (down about 0.7%)
• Underlying EPS Growth (H1 2026 vs. H1 2025): +8% at AXA, at the top of the 6% to 8% target range

Tired of scrolling through pages of figures to make sense of AXA? See the company’s full visual breakdown, including how its valuation stacks up against earnings and growth targets, in the company report for AXA.

AXA Earnings Power Starts To Match The Bull Story

Bulls argue AXA can compound higher quality earnings by growing in protection and health, tightening underwriting and using data and AI to lift margins. H1 2026 goes some way to backing that up. Underlying EPS rose 8% and return on equity was 18%, which points to real earnings power rather than just financial engineering.

The big test is whether core engines are pulling their weight. In P&C, earnings were up 6% with a 90.1% combined ratio and improving retail loss ratios, helped by 2 million net new personal lines contracts and lower reinsurance costs. In Life & Health, premiums grew 8%, earnings 11% and the health and protection combined ratio improved 130 bps to 96%. That is exactly where the bullish narrative wanted to see progress.

AI and analytics are present in management commentary on pricing and claims, although the financial impact is still described in broad efficiency gains rather than hard targets hit.

Access what the street is quietly baking into its multi year models for AXA, where the surface looks calm but the projected inflection points can be very different to the current €44.94 print, through the analyst estimates for AXA.

AXA Bear Case Hinges On Margins, Not Growth

The bearish narrative on AXA centers on two worries. That premium growth does not translate into cleaner margins and that underlying earnings rely too heavily on cycle and capital rather than disciplined underwriting. H1 2026 only partly answers that. P&C earnings rose with a 90.1% combined ratio, yet that ratio ticked higher and still benefits from a low 3.5% natural catastrophe load. Bears can argue the margin bar has not moved meaningfully higher.

Life & Health looks stronger, with 8% premium growth and 11% earnings growth plus a 130 bps combined ratio improvement to 96%. That undercuts fears of structural margin pressure in protection and health. However, AXA IM diluted group earnings growth and underlying net income excluding extra items declined about 4.3%. For critics who flag execution risk and sensitivity to softer profit pools, this is a clear milestone missed rather than closed.

After group earnings growth was diluted and net income excluding extra items declined, review our independent risk analysis for AXA which shows 1 important warning sign to expose potential hidden vulnerabilities.

Stay Ahead With AXA And Simply Wall St

If AXA’s 18% return on equity and underlying EPS growth have caught your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how the story develops. Once you decide to build or adjust a position, manage every holding in one place with the Portfolio Command Center that cuts through noise and highlights only the updates that matter. For a longer term view, tap into crowd insight and sentiment through the Community to see how other investors are thinking about AXA and similar stocks. By spotting potential catalysts and risks early, you give yourself a clearer edge with a better chance of staying ahead of the market.

Seeking Alternatives Beyond AXA?

Fresh ideas can move fast, and early momentum often fades once the crowd catches on. Scan these under the radar lists before the best entry points are gone and consider moving early.

• Identify cash-rich compounders before momentum is fully reflected in the price by running the list of solid balance sheet and fundamentals stocks (416 results), which still highlights companies that are flying under the radar for now.
• Explore income opportunities that may hold up when growth stories stall by scanning the 433 dividend fortresses before yields change and the most resilient payers become widely followed.
• Review potential AI infrastructure opportunities in advance of any major industry shifts by using the hand picked 55 AI infrastructure stocks while these names remain under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com